Mammalian-derived EBNA1 dGAr IgA

1. Mammalian-derived EBNA1 dGAr IgA predicts nasopharyngeal carcinoma in humans (AUC 0.939, 85.0% sensitivity, 94.8% specificity).

   “IgA to mammalian-derived EBNA1 dGAr achieved 85.0% sensitivity and 94.8% specificity (AUC, 0.939) for NPC status.”

   Humanswithin 4 years to diagnosis vs healthy controlsserum

   A high-throughput Epstein-Barr virus nuclear antigen 1 (EBNA1) serology test strip for nasopharyngeal carcinoma risk screening

   medRxiv : the preprint server for health sciences·27 Jul 2026Preprint

More on Nasopharyngeal carcinoma